plategra
egis pharmaceuticals plc - tikagreloras - plėvele dengtos tabletės - 60 mg - ticagrelor
plategra
egis pharmaceuticals plc - tikagreloras - plėvele dengtos tabletės - 90 mg - ticagrelor
ranogelan
g.l. pharma gmbh - ranolazinas - pailginto atpalaidavimo tabletės - 375 mg - ranolazine
ranogelan
g.l. pharma gmbh - ranolazinas - pailginto atpalaidavimo tabletės - 500 mg - ranolazine
ranogelan
g.l. pharma gmbh - ranolazinas - pailginto atpalaidavimo tabletės - 750 mg - ranolazine
ranolazine stada
stada arzneimittel ag - ranolazinas - pailginto atpalaidavimo tabletės - 375 mg - ranolazine
ranolazine stada
stada arzneimittel ag - ranolazinas - pailginto atpalaidavimo tabletės - 500 mg - ranolazine
ranolazine stada
stada arzneimittel ag - ranolazinas - pailginto atpalaidavimo tabletės - 750 mg - ranolazine
zokinvy
eigerbio europe limited - lonafarnib - progeria; laminopathies - kiti virškinimo trakto ir metabolizmo produktus, - zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of hutchinson-gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous lmna mutation with progerin-like protein accumulation or a homozygous or compound heterozygous zmpste24 mutation.
sunlenca
gilead sciences ireland unlimited company - lenacapavir sodium - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4. 2 ir 5. sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant hiv 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4. 2 ir 5.